Pros
It is healthcare and oncology, which should be a ‘pro’ but not in this environment
Cons
Other reviews referenced the massive attrition during 2021-2022 and that is accurate, and it was also preventable. New President of Ontada Susan Shiff arrived in Spring 2021 (Ontada public announcement March 22, 2021) and things started going downhill. Staff would leave and the response from leadership would be that positions couldn’t be re-filled, but Susan would deny that there was a “hiring freeze.” This disconnect created more distrust causing even more people to leave, and those positions were also not refilled. While Susan did hire other new executives, staff positions remained unfilled and Susan was openly dismissive of questions on this topic, even on town hall meetings. Attrition got even worse when Sagran Moodley arrived in the Fall 2021 as the new Chief Innovation and Technology Officer (Ontada public announcement November 3, 2021). Per other reviews on this site Sagran treated the existing staff with contempt and replaced existing technical leads with other managers he worked with from prior jobs with the same tendencies. Everything is going offshore. Ontada executives superficially care a lot about “employee opinion surveys” (a McKesson practice) in as much as it affects their bonuses, but for no other reason. Speaking up just made people a target. When employees left there were no exit interviews, and no interest in finding out why employees were leaving and what their frustrations were. Employees could put in a special request with HR for an exit interview, but that feedback went nowhere and was only to meet a legal minimum of pretending to listen. Ontada initially attracted a lot of employees who cared deeply about healthcare and oncology, and it also lost a great many for all the wrong reasons. McKesson (parent company of Ontada) CEO Brian Tyler might like to talk about “ICARE” values in the company but there isn’t much to show for it in Ontada.
